The FDA approved AstraZeneca's monotherapy for endometrial cancer, Imfinzi, after it was found in a study to decrease its risk of progression and death by 58% in patients who were diagnosed with advanced or recurrent endometrial cancer that is mismatch repair deficient.
The study was published in October in the Journal of Clinical Oncology. It found that overall Imfinzi was well tolerated and safety was consistent with previous trials, according to a June 17 news release from AstraZeneca.
Endometrial cancers that are mismatch repair deficient are often seen in 25% to 30% of patients, according to a study published in the International Journal of Gynecological Cancer.